|
PROXIMAGEN NEUROSCIENCE PLC
(Proximagen or the Company)
APPOINTMENT OF MICHAEL ASHTON AS NON-EXECUTIVE DIRECTOR
London, UK, 15 December 2005 - Proximagen Neuroscience plc (AIM: PRX), the specialty drug discovery and development company focused on neurodegenerative diseases, is pleased to announce the appointment of Michael Ashton as a Non-Executive Director with immediate effect.
Michael Ashton, aged 59, is Chief Executive Officer of SkyePharma plc. He became Chief Executive in November 1998 having served on the Board since March 1997. Michael has over 32 years of experience in the pharmaceutical industry having worked for Merck Inc., Pfizer Inc., Purepac Inc. and prior to joining SkyePharma, Faulding Inc., where he was Chairman, President and CEO. He is currently Non-Executive Director of Transition Therapeutics Inc., Astralis Limited, Vital Living Inc and Hikma Pharmaceuticals plc.
The company also wishes to announce that George Murlewski, a Non-Executive Director, is retiring from the Board with effect from 31 December 2005. Mr Murlewski, is spin-out company mentor at King's College.
Commenting on Michael Ashton's appointment, Kenneth Mulvany, Chief Executive Officer of Proximagen, said:
"I am delighted to have attracted an executive of Michael Ashton's stature to our Board. His experience with public company leadership will be invaluable as we progress Proximagen's business forward. I would also like to take this opportunity to thank George who made a very valuable contribution to Proximagen during its formative period."
Proximagen confirms that, save for the above, there are no other matters under
paragraph (g) of Schedule 2 of the AIM rules to be announced.
For more information please contact:
Proximagen Neuroscience plc (www.proximagen.com)
020 7848 6011
Kenneth Mulvany, Chief Executive Officer
James Hunter, Financial Controller
Buchanan Communications
020 7466 5000
Tim Anderson / Mark Court / Mary-Jane Johnson
About Proximagen
Proximagen is a drug discovery and development company that is primarily focused on the identification and subsequent out-licensing of novel therapeutics to improve the quality of life for patients suffering from neurodegenerative disease such as Parkinson's disease and Alzheimer's disease.
The Company was founded by Professor Peter Jenner in conjunction with King's College in November 2003 to draw upon over 25 years of pre-eminent neurodegenerative research.
Proximagen joined the AIM market of the London Stock Exchange in March 2005.
| 
